ロード中...
A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring
BACKGROUND: Biologics have gained traction for use in oncology, but have demonstrate clinical variability for efficacy and safety. Therapeutic drug monitoring (TDM) can benefit patients’ outcomes from a biologic therapy when the latter has a defined therapeutic window. A clinically relevant therapeu...
保存先:
| 出版年: | Onco Targets Ther |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5749565/ https://ncbi.nlm.nih.gov/pubmed/29343970 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S153056 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|